Pédiatrique divers

  • Accueil
  • Pédiatrique divers
  • COG-APEC14B1

TITRE Le projet : un protocole pour chaque enfant : Registre, Éligibilité et Étude de la Biologie et des Résultats.
PROTOCOLE ID COG-APEC14B1
CLINICAL TRIAL.gov ID NCT02402244
TYPE(S) DE CANCER Pédiatrique divers
PHASE
TYPE D'ÉTUDE
INSTITUTION CENTRE UNIVERSITAIRE DE SANTE MCGILL
1001 boul. Décarie
VILLE Montréal
INVESTIGATEUR(RICE) PRINCIPAL(E) Sharon Abish
COORDONATEUR(RICE) Margaret Hin-Chan
mch.rho@muhc.mcgill.ca
514-412-4400 poste 23543 Katia Pamphile
mch.rho@muhc.mcgill.ca
514-412-4400 poste 22592
STATUT  Actif en recrutement
CRITÈRES D'ÉLIGIBILITÉ (EN)
  • Enrollment can occur at any time after disease presentation including at time of disease progression or recurrence; for patients who are to be enrolled on COG therapeutic studies, enrollment on APEC14B1 must occur prior to enrollment onto the therapeutic trial

  • Patients with a known or suspected neoplasm that occurs in the pediatric, adolescent or young adult populations are eligible for enrollment as follows:

  • All cancer cases with an International Classification of Diseases for Oncology (ICD-O) histologic behavior code of two "2" (carcinoma in situ) or three "3" (malignant)
  • All neoplastic lesions of the central nervous system regardless of behavior, i.e., benign, borderline or malignant

  • Other benign/borderline conditions including:

  • Mesoblastic nephroma
  • Teratomas
  • Myeloproliferative diseases including transient myeloproliferative disease
  • Langerhan cell histiocytosis
  • Lymphoproliferative diseases
  • Subjects must be =< 25 years of age at time of original diagnosis, except for patients who are being screened specifically for eligibility onto a COG (or COG participating National Clinical Trials Network (NCTN) ) therapeutic study, for whom there is a higher upper age limit
  • All patients or their parents or legally authorized representatives must sign a written informed consent; parents will be asked to sign a separate consent for their own biospecimen submission
CRITÈRES D'EXCLUSION (EN)